Man Claims Centocor Concealed Remicade Cancer Risk to Maintain Profits

PHILADELPHIA - Centocor Inc. chose to put its financial success ahead of the safety of consumers of its arthritis treatment Remicade by actively concealing information associated with the medicine's potential to increase the risk of developing cancer, an Oregon plaintiff alleges in a wrongful death lawsuit. Brame v. Centocor Inc., et al., No. 06-4871 (E.D. Pa.).

Kerry Brame filed the complaint Nov. 1 on behalf of his deceased mother, Ida Brame, 51, who died of metastatic renal cell carcinoma on June 23.

According to the complaint, filed in the U.S. District Court for the Eastern District of Pennsylvania, Ida Brame …